Assessment of Dose-Dependent Response to Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial

被引：0

作者：

Platzbecker, Uwe ^{[1
]}

Fenaux, Pierre ^{[2
]}

Mufti, Ghulam J. ^{[3
]}

Garcia-Manero, Guillermo ^{[4
]}

Komrokji, Rami S. ^{[5
]}

Buckstein, Rena ^{[6
]}

Diez-Campelo, Maria ^{[7
]}

Finelli, Carlo ^{[8
]}

Sekeres, Mikkael A. ^{[9
]}

Selleslag, Dominik ^{[10
]}

DeZern, Amy E. ^{[11
]}

Quesnel, Bruno ^{[12
]}

Beyne-Rauzy, Odile ^{[13
]}

Voso, Maria Teresa ^{[14
]}

Greenberg, Peter L. ^{[15
]}

Zeidan, Amer M. ^{[16
,17
]}

Ades, Lionel ^{[2
]}

Verma, Amit ^{[18
]}

Savona, Michael R. ^{[19
]}

Laadem, Abderrahmane ^{[20
]}

Ito, Rodrigo ^{[20
]}

Zhang, Jennie ^{[20
]}

Rampersad, Anita ^{[20
]}

Morison, Jessica ^{[20
]}

Louis, Chrystal ^{[20
]}

Linde, Peter G. ^{[21
]}

Santini, Valeria ^{[22
]}

机构：

[1] Univ Hosp Leipzig, Med Clin & Policlin 1, Hematol & Cellular Therapy, Leipzig, Germany

[2] Univ Paris 07, Serv Hematol Seniors, Hop St Louis, Paris, France

[3] Kings Coll London, Dept Haematooncol, London, England

[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[6] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada

[7] Univ Hosp Salamanca, Inst Biomed Res Salamanca, Hematol Dept, Salamanca, Spain

[8] S Orsola Malpighi Univ Hosp, Dept Oncol & Hematol, Bologna, Italy

[9] Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

[10] Acad Hosp St Jan, Dept Haematol, Brugge, Belgium

[11] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[12] Ctr Hosp Univ Lille, Serv Malad Sang, Hop Huriez, Lille, France

[13] Inst Univ Canc Toulouse Oncopole, Med Interne, Toulouse, France

[14] Univ Roma Tor Vergata, Dipartimento Biopatol & Diagnost Immagini, Rome, Italy

[15] Stanford Univ, Canc Ctr, Stanford, CA 94305 USA

[16] Yale Univ, Dept Internal Med, Yale Sch Med, New Haven, CT USA

[17] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[18] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, New York, NY USA

[19] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA

[20] Bristol Myers Squibb, Princeton, NJ USA

[21] Acceleron Pharma, Cambridge, MA USA

[22] Univ Florence, Azienda Osped Univ AOU Careggi, MDS Unit, Florence, Italy

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

MDS; clinical trial; phase III; myelodysplastic syndromes;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDS-175

引用

页码：S318 / S318

页数：1

共 50 条

[21] Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study
Platzbecker, Uwe
Santini, Valeria
Komrokji, Rami S.
Zeidan, Amer M.
Garcia-Manero, Guillermo
Buckstein, Rena J.
Rose, Shelonitda
Fabre, Shannon
Miteva, Dimana
Zhang, Jennie
Yucel, Aylin
Hughes, Christina
Fenaux, Pierre
BLOOD, 2021, 138
[22] Longer-Term RBC Transfusion Reduction in the Phase III MEDALIST Study of Luspatercept in Patients With Lower-Risk MDS With Ring Sideroblasts
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 14 - 14
[23] GDF11/SMAD Regulated Splicing of GATA1 Is Associated with Response to Luspatercept in Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Aluri, Srinivas
Fraint, Ellen
Chakraborty, Samarpana
Ahsan, Aarif
Poigailwar, Gowri
Zhao, Rongbao
Pradhan, Kith
Bachiashvili, Kimo
Budhathoki, Anjali
Agarwal, Beamon
Mitchell, Shanisha Gordon
Carbajal, Milagros
Sahu, Srabani
Boultwood, Jacqueline
Pellagatti, Andrea
Steidl, Ulrich
Wickrema, Amittha
Nandakumar, Satish
Shastri, Aditi
Bowman, Teresa
Vodala, Sadanand
Verma, Amit K.
BLOOD, 2023, 142
[24] Real World Efficacy of Luspatercept in Patients with Lower-risk Myelodysplastic Syndromes/Neoplasms (LR-MDS); a Single Center Study in a Heavily Pretreated Cohort
Kometas, Marisa
Hyak, Jonathan
Hoff, Fieke
Irizarry-Gatell, Vivian
Marinos, Alejandro
Jackson, Clayton
Anderson, Julia
Kalkan, Fatma
Ramakrishnan, Praveen
Afrough, Aimaz
Wolfe, Heather
Khan, Adeel
Anderson, Larry
Awan, Farrukh
Kaur, Gurbakhash
Yilmaz, Elif
Alvarenga, Julio
Chen, Weina
Weinberg, Olga
Cantu, Miguel
Collins, Robert H.
Chung, Stephen S.
Madanat, Yazan F.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S389 - S389
[25] Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
Zeidan, Amer M.
Platzbecker, Uwe
Garcia-Manero, Guillermo
Sekeres, Mikkael A.
Fenaux, Pierre
DeZern, Amy E.
Greenberg, Peter L.
Savona, Michael R.
Jurcic, Joseph G.
Verma, Amit K.
Mufti, Ghulam J.
Buckstein, Rena
Santini, Valeria
Shetty, Jeevan K.
Ito, Rodrigo
Zhang, Jennie
Zhang, George
Ha, Xianwei
Backstrom, Jay T.
Komrokji, Rami S.
BLOOD, 2022, 140 (20) : 2170 - 2174
[26] Hematologic and transfusion outcomes in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept: Real-world assessment in the community practice setting
Mukherjee, Sudipto
Brown-Bickerstaff, Cherrishe
Falkenstein, Angelica
Makinde, Adeola Y.
Bland, Emily
Laney, JaLyna
Garretson, Marne Prime
McBride, Ali
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[27] Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
Oliva, Esther Natalie
Platzbecker, Uwe
Garcia-Manero, Guillermo
Mufti, Ghulam J.
Santini, Valeria
Sekeres, Mikkael A.
Komrokji, Rami S.
Shetty, Jeevan K.
Tang, Derek
Guo, Shien
Liao, Weiqin
Zhang, George
Ha, Xianwei
Ito, Rodrigo
Lord-Bessen, Jennifer
Backstrom, Jay T.
Fenaux, Pierre
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (01)
[28] LUSPATERCEPT RESPONSE IN NEW SUBPOPULATIONS OF PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): UPDATE OF THE PACE STUDY
Platzbecker, U.
Germing, U.
Goetze, K.
Kiewe, P.
Wolff, T.
Mayer, K.
Chromik, J.
Radsak, M.
Wilson, D.
Zhang, X.
Laadem, A.
Sherman, M.
Attie, K.
Linde, P.
Giagounidis, A.
LEUKEMIA RESEARCH, 2017, 55 : S31 - S31
[29] Impact of Luspatercept on Healthcare Resource Use (HCRU) Among Patients with Lower-Risk, Myelodysplastic Syndromes (LR-MDS): A Medical Record Review in Canada, Germany, and Spain
Diez-Campelo, Maria
Esterberg, Elizabeth
Goyal, Ravi K.
Glassberg, Mrudula B.
Yucel, Aylin
Rombi, Julien
Davis, Keith L.
Jimenez, Maria
Miteva, Dimana
Hnoosh, Ahmed
Germing, Ulrich
BLOOD, 2024, 144 : 5055 - 5056
[30] Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns
Mukherjee, Sudipto
Brown-Bickerstaff, Cherrishe
McBride, Ali
Gajra, Ajeet
Gentile, Danielle
Falkenstein, Angelica
Miller, Talia
Laney, JaLyna
Savill, Kristin M.
Makinde, Adeola Y.
BLOOD, 2022, 140

← 1 2 3 4 5 →